TSE:4523Pharmaceuticals
The Bull Case For Eisai (TSE:4523) Could Change Following New Four-Year Lecanemab Data Release - Learn Why
Eisai has announced that it will present new long-term data on its Alzheimer’s drug lecanemab, including four-year results from the Clarity AD Open-Label Extension trial and real-world safety and efficacy findings in specific patient groups, at the AD/PD 2026 conference held in March 2026.
This wave of extended and real-world lecanemab data, plus Eisai’s prominent role hosting an industry symposium, sharpens attention on how thoroughly the drug could reshape Alzheimer’s treatment...